Artwork
iconShare
 
Manage episode 492550425 series 2943386
Content provided by Numinus Network. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Numinus Network or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://staging.podcastplayer.com/legal.

Send us a text

The path to FDA approved prescribable medicine has been a long and precarious one for psychedelics. However, recent reports by some of the major players in the psychedelic medicine space show promising results from clinical trials involving psilocybin and 5-MeO-DMT.
In today’s episode of the Psychedelic Therapy Frontiers podcast, we review the topline data from these recent reports and explore what the future of psychedelic therapies might look like for people struggling with mental health conditions.
For those of you who are new to the show, welcome! Psychedelic Therapy Frontiers is brought to you by Numinus Network and is hosted by Dr. Steve Thayer and Dr. Reid Robison.

Learn more about our podcast at https://numinusnetwork.com/learn/podcast/
Learn more about psychedelic therapy training opportunities at https://numinusnetwork.com/training/
Learn more about our clinical trials at https://www.numinusnetwork.com/research
Learn more about Numinus at https://numinusnetwork.com/
Email us at [email protected]
Follow us on Instagram:
https://www.instagram.com/drstevethayer/
https://www.instagram.com/innerspacedoctor/
https://www.instagram.com/numinushealth/

  continue reading

212 episodes